Valuation: Positron Corporation

Market Cap 5.98Cr 5.12Cr 4.79Cr 4.39Cr 8.23Cr 571.96Cr 8.34Cr 57Cr 22Cr 287.32Cr 22Cr 22Cr 950.34Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.86Cr 5.02Cr 4.7Cr 4.3Cr 8.07Cr 561.09Cr 8.18Cr 56Cr 22Cr 281.86Cr 22Cr 22Cr 932.28Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day-5.49%
1 week-4.99%
Current month-2.38%
1 month+2.38%
3 months-3.91%
6 months-25.86%
Current year+2.99%
1 week 1.66
Extreme 1.66
1.82
1 month 1.45
Extreme 1.45
1.88
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-5.39%-4.99%-7.03%+32.31% 5.98Cr
-3.63%-3.01%-18.48%-19.22% 1.34TCr
+2.01%+3.15%+28.29%+17.21% 460.88Cr
-0.05%-0.72%-40.01%-50.54% 130.75Cr
-3.38%-2.96%-37.36%-37.18% 120.63Cr
-7.45%-18.43%-41.03% - 114.5Cr
+0.62%+0.54%+23.95%+82.47% 110.84Cr
-0.58%-6.09%+45.70%+133.17% 56Cr
+1.86%-6.35%+52.01% - 30Cr
-1.91%-1.79%-63.44%+279.40% 26Cr
Average -1.82%-2.90%-5.74%+54.70% 239.21Cr
Weighted average by Cap. -2.17%-1.68%-8.80%-2.10%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.62Cr 8L 55.63L 21.7L 2.82Cr 22.06L 21.58L 9.34Cr 5L 4L 4L 3L 6L 4.42Cr 6L 43.7L 17.04L 2.22Cr 17.33L 16.95L 7.34Cr
Net income -23.79L -20.38L -19.07L -17.45L -32.76L -23Cr -33.19L -2.25Cr -87.86L -11Cr -89.33L -87.39L -38Cr -1.06Cr -90.83L -84.99L -77.79L -1.46Cr -101.45Cr -1.48Cr -10Cr -3.92Cr -51Cr -3.98Cr -3.89Cr -168.57Cr
Net Debt 14.24L 12.2L 11.42L 10.45L 19.61L 14Cr 19.87L 1.35Cr 52.6L 6.85Cr 53.49L 52.32L 23Cr -11.36L -10L -9L -8L -15.64L -11Cr -15.85L -1.08Cr -41.96L -5.46Cr -42.66L -41.73L -18Cr
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
22/26/22 $1.722 -5.39% 34,608
20/26/20 $1.820 +2.25% 8,030
19/26/19 $1.780 -1.66% 3,762
18/26/18 $1.810 +5.23% 3,600
17/26/17 $1.720 -4.99% 3,446
  1. Stock Market
  2. Stocks
  3. POSC Stock